JP2010535747A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535747A5
JP2010535747A5 JP2010519489A JP2010519489A JP2010535747A5 JP 2010535747 A5 JP2010535747 A5 JP 2010535747A5 JP 2010519489 A JP2010519489 A JP 2010519489A JP 2010519489 A JP2010519489 A JP 2010519489A JP 2010535747 A5 JP2010535747 A5 JP 2010535747A5
Authority
JP
Japan
Prior art keywords
triazolo
pyridazin
sulfanyl
benzothiazol
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010519489A
Other languages
English (en)
Japanese (ja)
Other versions
JP5694767B2 (ja
JP2010535747A (ja
Filing date
Publication date
Priority claimed from FR0705789A external-priority patent/FR2919870B1/fr
Priority claimed from FR0801819A external-priority patent/FR2929613B1/fr
Application filed filed Critical
Priority claimed from PCT/FR2008/001172 external-priority patent/WO2009056692A2/fr
Publication of JP2010535747A publication Critical patent/JP2010535747A/ja
Publication of JP2010535747A5 publication Critical patent/JP2010535747A5/ja
Application granted granted Critical
Publication of JP5694767B2 publication Critical patent/JP5694767B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010519489A 2007-08-09 2008-08-06 新規な6−トリアゾロピリダジンスルファニルベンゾチアゾールおよびベンゾイミダゾールの誘導体、これらの製造方法、薬剤および医薬組成物としての適用ならびにmet阻害剤としての新規な使用 Expired - Fee Related JP5694767B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR07/05789 2007-08-09
FR0705789A FR2919870B1 (fr) 2007-08-09 2007-08-09 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
FR08/01819 2008-04-02
FR0801819A FR2929613B1 (fr) 2008-04-02 2008-04-02 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
PCT/FR2008/001172 WO2009056692A2 (fr) 2007-08-09 2008-08-06 Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Publications (3)

Publication Number Publication Date
JP2010535747A JP2010535747A (ja) 2010-11-25
JP2010535747A5 true JP2010535747A5 (enExample) 2014-01-23
JP5694767B2 JP5694767B2 (ja) 2015-04-01

Family

ID=40524792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010519489A Expired - Fee Related JP5694767B2 (ja) 2007-08-09 2008-08-06 新規な6−トリアゾロピリダジンスルファニルベンゾチアゾールおよびベンゾイミダゾールの誘導体、これらの製造方法、薬剤および医薬組成物としての適用ならびにmet阻害剤としての新規な使用

Country Status (41)

Country Link
US (3) US8546393B2 (enExample)
EP (1) EP2178881B1 (enExample)
JP (1) JP5694767B2 (enExample)
KR (1) KR101654376B1 (enExample)
CN (1) CN101801973B (enExample)
AR (1) AR068055A1 (enExample)
AU (1) AU2008320791B2 (enExample)
BR (1) BRPI0815606A2 (enExample)
CA (2) CA2884102A1 (enExample)
CL (1) CL2008002351A1 (enExample)
CO (1) CO6251270A2 (enExample)
CR (1) CR11252A (enExample)
CY (1) CY1114906T1 (enExample)
DK (1) DK2178881T3 (enExample)
DO (1) DOP2010000040A (enExample)
EA (1) EA023465B1 (enExample)
EC (1) ECSP109944A (enExample)
ES (1) ES2436657T3 (enExample)
GT (1) GT201000023A (enExample)
HR (1) HRP20131182T1 (enExample)
IL (1) IL203734A (enExample)
JO (1) JO2935B1 (enExample)
MA (1) MA31685B1 (enExample)
ME (1) ME00972B (enExample)
MX (2) MX340060B (enExample)
MY (1) MY152535A (enExample)
NI (1) NI201000022A (enExample)
NZ (1) NZ583177A (enExample)
PA (1) PA8792501A1 (enExample)
PE (1) PE20090900A1 (enExample)
PL (1) PL2178881T3 (enExample)
PT (1) PT2178881E (enExample)
RS (1) RS53078B (enExample)
SG (1) SG183077A1 (enExample)
SI (1) SI2178881T1 (enExample)
TN (1) TN2010000026A1 (enExample)
TW (1) TWI429649B (enExample)
UA (1) UA101328C2 (enExample)
UY (1) UY31277A1 (enExample)
WO (1) WO2009056692A2 (enExample)
ZA (1) ZA201000912B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
FR2941229B1 (fr) * 2009-01-21 2012-11-30 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AU2009272517A1 (en) * 2008-07-18 2010-01-21 Sanofi-Aventis Novel imidazo[1,2-a]pyridine derivatives, method for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use in particular as MET inhibitors
WO2010007316A2 (fr) * 2008-07-18 2010-01-21 Sanofi-Aventis NOUVEAUX DERIVES TRIAZOLO(4,3-a)PYRIDINE,LEUR PROCEDE DE PREPARATION,LEUR APPLICATION A TITRE DE MEDICAMENTS,COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
FR2941949B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) * 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
EP2396333B1 (en) * 2009-02-10 2013-07-03 AstraZeneca AB Triazolo[4,3-b]pyridazine derivatives and their uses for prostate cancer
UY32623A (es) * 2009-05-11 2010-12-31 Astrazeneca Ab Derivados bicíclicos para afecciones asociadas al receptor de andrógenos
MX336996B (es) 2009-12-31 2016-02-09 Hutchison Medipharma Ltd Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus metodos de uso.
FR2958292A1 (fr) * 2010-03-30 2011-10-07 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
TW201202242A (en) 2010-03-30 2012-01-16 Sanofi Aventis 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors
FR2966151B1 (fr) * 2010-10-14 2012-11-09 Sanofi Aventis Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
AR085183A1 (es) 2010-07-30 2013-09-18 Lilly Co Eli Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての6−置換3−(キノリン−6−イルチオ)−[1,2,4]トリアゾロ[4,3−a]ピラジン
EP2872119A1 (en) * 2012-07-12 2015-05-20 Sanofi Anti-tumoral composition comprising the compound 1-(6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-ylethyl)urea
WO2014076162A1 (en) 2012-11-19 2014-05-22 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
TWI695837B (zh) 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10047071B1 (en) 2018-01-15 2018-08-14 King Saud University Dihydropyrimidinone derivatives
CN110317216A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑并哒嗪类衍生物在医药领域的应用
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110041311B (zh) * 2019-05-20 2021-03-19 东南大学 一种荧光探针分子ml-fp及其制备方法和应用
WO2020251911A1 (en) * 2019-06-12 2020-12-17 Bristol-Myers Squibb Company Crystalline salt forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499995A1 (fr) 1981-02-13 1982-08-20 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus.
US6528510B1 (en) * 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
EP1963329B1 (en) * 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
NZ568807A (en) * 2005-12-21 2011-05-27 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
WO2008051808A2 (en) * 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.

Similar Documents

Publication Publication Date Title
JP2010535747A5 (enExample)
AU2014304562B2 (en) Thieno(2,3-c)pyrans as CFTR modulators
PE20090506A1 (es) DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
JP2012097115A5 (enExample)
JP2013510178A5 (enExample)
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
JP2014525432A5 (enExample)
US10065972B2 (en) Bicyclic or tricyclic heterocyclic compound
JP2017510576A5 (enExample)
JP2012511588A5 (enExample)
JP2013144679A5 (enExample)
PE20091468A1 (es) DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
TW201443048A (zh) 氮雜苯并咪唑化合物
JP2014503544A5 (enExample)
JP2016531108A5 (enExample)
CA2925743C (en) Novel bicyclic pyridinones as gamma-secretase modulators
JP6455947B2 (ja) ホスホジエステラーゼ10aインヒビターとしての縮合トリアゾール誘導体
JPWO2017069275A1 (ja) 新規二環性複素環化合物
JP2017525717A5 (enExample)
JP2011519913A5 (enExample)
WO2010039825A3 (en) Imidazo [1, 2-a] pyridine compounds as receptor tyrosine kinase inhibitors
PH12016501481A1 (en) Ethynyl derivatives
RU2016129189A (ru) Производные 3-(5-хлор-2-оксобензо[d]оксазол-3(2н)-ил)пропановой кислоты в качестве кмо ингибиторов
JP2017081908A (ja) 医薬組成物
JPWO2014069554A1 (ja) キヌクリジンアミド誘導体及びその医薬用途